Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Long-Term Investments (2022 - 2024)

Zentalis Pharmaceuticals (ZNTL) has 3 years of Long-Term Investments data on record, last reported at $389.4 million in Q2 2024.

  • For Q2 2024, Long-Term Investments changed N/A year-over-year to $389.4 million; the TTM value through Jun 2024 reached $389.4 million, changed N/A, while the annual FY2023 figure was $454.9 million, 2044.35% up from the prior year.
  • Long-Term Investments reached $389.4 million in Q2 2024 per ZNTL's latest filing, down from $451.4 million in the prior quarter.
  • Across five years, Long-Term Investments topped out at $454.9 million in Q4 2023 and bottomed at $18.9 million in Q1 2023.
  • Average Long-Term Investments over 3 years is $178.7 million, with a median of $33.1 million recorded in 2022.
  • Peak YoY movement for Long-Term Investments: tumbled 47.12% in 2023, then surged 2287.81% in 2024.
  • A 3-year view of Long-Term Investments shows it stood at $21.2 million in 2022, then surged by 2044.35% to $454.9 million in 2023, then fell by 14.39% to $389.4 million in 2024.
  • Per Business Quant database, its latest 3 readings for Long-Term Investments were $389.4 million in Q2 2024, $451.4 million in Q1 2024, and $454.9 million in Q4 2023.